Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Amnah Almulhim, Yasir Shaikh, Lenah Shaikh, Ahad Shaikh
King Fahad Specialist Hospital, Saudi Arabia
Scientific Tracks Abstracts: J Clin Exp Dermatol Res
Atopic dermatitis (AD) is a common disease that affects different age groups ranging from mild to severe. For a patient with severe atopic dermatitis, systemic treatment options are limited, the first biological medication approved for the treatment of AD is dupilumab. Dupilumab was initially approved by the food and drug administration (FDA) for the treatment of adults with AD followed by adolescents and recently approved for the treatment of pediatrics with AD. Like other approved medication some side effects are not reported before the phase III trial. Thereby we present a case of dupilumab induced facial erythema treated with oral and topical antifungal. We believe the incidence if facial erythema in patients taking dupilumab is low, however it is still encounterable with limited described data. Our patient responded to topical antifungal better than oral, thus we recommend a trail of topical treatment as a first line for dupilumab induced facial erythema.
Amnah Almulhim is dermatology assistant consultant with humble experience in evaluating and managing dermatological diseases. She presented this case after successfully treating observed side effect. Her recommended treatment option is described due to the lack of treatment consensus for such encounter. Treatment needs to be tried on more patients to have definitive result.